Table 3.

Medication for opioid use disorder (MOUD) characteristics among individuals who were prescribed an MOUD while incarcerated in Vermont.

	A) Pre-MOUD implementation & pre-COVID-19 (n = 39)	B) Post-MOUD implementation & pre-COVID-19 (n = 1918)	C) Post-MOUD implementation & during COVID-19 (n = 779)
A. MOUD type
Buprenorphine, n (%)	26 (66.7)	1585 (82.6)	654 (84.0)
Methadone, n (%)	13 (33.3)	268 (14.0)	112 (14.4)
Naltrexone, n (%)	0 (0)	65 (3.4)	13 (1.7)
Buprenorphine vs other MOUD OR (95% CI)	Referent	2.3 (1.2, 4.6)	2.6 (1.3, 3.9)
	–	Referent	1.1 (0.9, 1.4)
B. MOUD initiation, continuation, or discontinuation
Initiated any MOUD, n (%)	16 (41.0)	1210 (63.1)	420 (53.9)
Continued any MOUD, n (%)	23 (59.0)	708 (36.9)	359 (46.1)
Initiation vs continuation OR (95% CI)	Referent	2.5 (1.3, 4.7)	1.7 (0.9, 3.2)
	–	Referent	0.7 (0.6, 0.8)
Discontinued any MOUD, n (%)	0 (0)	307 (16.0)	62 (8.0)
Discontinued vs did not discontinue OR (95% CI)	–	Referent	0.5 (0.3, 0.6)

Bolded text = statistically significant (p < .05); CI=Confidence interval; MOUD = Medication for opioid use disorder; OR = Odds ratio.